Sol-Gel Technologies Current Ratio 2016-2019 | SLGL

Sol-Gel Technologies current ratio from 2016 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Sol-Gel Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.06B $0.01B 8.29
2018-12-31 $0.07B $0.01B 13.48
2018-06-30 $0.08B $0.00B 20.77
2018-03-31 $0.09B $0.00B 43.22
2017-12-31 $0.00B 0.00
2017-09-30 $0.02B $0.07B 0.25
2017-06-30 $0.00B 0.00
2016-12-31 $0.01B $0.04B 0.20
2015-12-31 $0.01B $0.02B 0.32
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.185B $0.000B
Sol-Gel Technologies a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies based in Israel.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.484B 9.74
Mylan (MYL) United Kingdom $9.330B 4.08
Bausch Health Cos (BHC) Canada $8.157B 5.57
Teva Pharmaceutical Industries (TEVA) Israel $8.044B 3.15
Dr Reddy's Laboratories (RDY) India $6.263B 23.43
ASPEN PHARMACR (APNHY) South Africa $3.213B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.677B 16.76
Amphastar Pharmaceuticals (AMPH) United States $0.912B 51.00
Homology Medicines (FIXX) United States $0.907B 0.00
Voyager Therapeutics (VYGR) United States $0.896B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.580B 0.87
Akorn (AKRX) United States $0.483B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.446B 0.00
CymaBay Therapeutics (CBAY) United States $0.427B 0.00
Assembly Biosciences (ASMB) United States $0.332B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.228B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.165B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.057B 0.00